Kalvista Pharmaceuticals Stock Investor Sentiment
| KALV Stock | USD 11.40 0.71 6.64% |
Slightly above 51% of Kalvista Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Kalvista Pharmaceuticals suggests that many traders are impartial. Kalvista Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Kalvista Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Kalvista |
Kalvista Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Kalvista Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Kalvista Pharmaceuticals that are available to investors today. That information is available publicly through Kalvista media outlets and privately through word of mouth or via Kalvista internal channels. However, regardless of the origin, that massive amount of Kalvista data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Kalvista Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Kalvista Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Kalvista Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Kalvista Pharmaceuticals alpha.
Kalvista Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Audhya Paul K. of 5000 shares of Kalvista Pharmaceuticals subject to Rule 16b-3 | 11/29/2024 |
2 | Disposition of 15625 shares by Benjamin Palleiko of Kalvista Pharmaceuticals subject to Rule 16b-3 | 12/06/2024 |
3 | Disposition of 7627 shares by Benjamin Palleiko of Kalvista Pharmaceuticals at 9.75 subject to Rule 16b-3 | 12/09/2024 |
4 | KalVista Appoints Jeb Ledell as Chief Operating Officer | 12/16/2024 |
5 | Insider Trading | 01/30/2025 |
6 | Acquisition by Venrock Healthcare Capital Partners Iii, L.p. of 11754 shares of Kalvista Pharmaceuticals at 8.89 subject to Rule 16b-3 | 02/03/2025 |
7 | KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 02/04/2025 |
8 | Venrock Healthcare Capital Par Purchases 43,707 Shares of KalVista Pharmaceuticals, Inc. Stock | 02/06/2025 |
9 | Acquisition by Venrock Healthcare Capital Partners Iii, L.p. of 73649 shares of Kalvista Pharmaceuticals at 9.29 subject to Rule 16b-3 | 02/07/2025 |
10 | KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma Immunology 2025 Annual Meeting | 02/10/2025 |
11 | Acquisition by Venrock Healthcare Capital Partners Iii, L.p. of 26703 shares of Kalvista Pharmaceuticals at 9.18 subject to Rule 16b-3 | 02/11/2025 |
12 | Acquisition by Venrock Healthcare Capital Partners Iii, L.p. of 100000 shares of Kalvista Pharmaceuticals at 9.23 subject to Rule 16b-3 | 02/12/2025 |
13 | Disposition of 2419 shares by Benjamin Palleiko of Kalvista Pharmaceuticals subject to Rule 16b-3 | 02/14/2025 |
14 | Disposition of 5104 shares by Benjamin Palleiko of Kalvista Pharmaceuticals at 9.8242 subject to Rule 16b-3 | 02/18/2025 |
15 | Acquisition by Christopher Yea of 4204 shares of Kalvista Pharmaceuticals subject to Rule 16b-3 | 02/19/2025 |
16 | KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma Immunology 2025 Annual Meeting | 02/21/2025 |
17 | Disposition of 1918 shares by Christopher Yea of Kalvista Pharmaceuticals at 10.02 subject to Rule 16b-3 | 02/24/2025 |
18 | KalVista Pharmaceuticals, Inc. Insider Paul K. Audhya Sells 2,394 Shares of Stock | 02/26/2025 |
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.